Ketorolaco Genfar

Ketorolac

Method of action: Analgesic, Analgetic, Anti-Inflammatory, Antipyretic, Nonsteroidal Anti-Inflammatory, Ophthalmologic Agent, Ophthalmologicals

Treatment option: Pain, Toothache, Colic, Surgery

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ketorolaco Genfar

This overview defines the identity and classification of Ketorolaco Genfar, focusing on its composition, general purpose, and recognized features.

Property	Description
Active ingredient	Ketorolac tromethamine
Form	Tablet, Injectable solution, Ophthalmic solution
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	Analgesia and reduction of inflammation
Origin	Synthetic compound

Identity and Pharmacological Classification of Ketorolaco Genfar

Ketorolaco Genfar is a medicine that belongs to the pharmacological class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), specifically recognized for its powerful analgesic effect.

The core of this medicine is the active ingredient Ketorolac tromethamine, a synthetic compound that defines its therapeutic function. Ketorolac is a widely used nonsteroidal anti-inflammatory agent available in various preparations. This classification is clinically recognized by medical protocols for its potent analgesic capacity, distinguishing it from common over-the-counter NSAIDs. Ketorolaco Genfar is specifically associated with the manufacturer Genfar and is designated as a prescription-only medicine (POM), aligning its use with professional medical oversight.

Physical Forms and Single-Ingredient Composition

The medicine is a single-ingredient product, and the active substance is supplied in several key pharmaceutical preparations to facilitate diverse routes of administration.

These preparations include tablets for oral ingestion, injectable solutions for parenteral delivery (into a muscle or vein), and an ophthalmic solution for targeted eye treatment. As a single-ingredient product, its therapeutic effect relies exclusively on the Ketorolac component. The use of Ketorolac is established for symptomatic relief across these various forms. The availability of an injectable solution in particular underscores its positioning for scenarios where rapid, systemic action is required. The base or vehicle for the medicine varies with the form, utilizing an appropriate pharmaceutical vehicle to ensure effective delivery of the active substance.

General Purpose: Analgesia and Anti-Inflammation

The general purpose of Ketorolaco Genfar is to provide relief by acting as a highly effective non-opioid analgesic and anti-inflammatory agent.

Its classification as an NSAID directly implies its function: to dampen the body’s inflammatory response, reducing discomfort, swelling, and redness. This drug provides relief by interfering with the chemical production of pain signals. This general therapeutic purpose positions the drug as a significant option for the symptomatic management of physical distress across adult patient groups.

What side effects are possible with Ketorolaco Genfar?

Possible Side Effects and Safety Information

The safety profile of ketorolac tromethamine, the active ingredient, is strictly defined by government regulatory bodies based on documented adverse reactions and use restrictions.

Serious and Clinically Significant Risks

Official regulatory documents feature prominent warnings regarding the potential for serious, life-threatening adverse events:

Gastrointestinal (GI) Risk: Risk of severe GI events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events may occur at any time without warning symptoms.
Cardiovascular (CV) Risk: Increased risk of serious CV thrombotic events, such as myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with duration of use.
Bleeding Risk: Inhibits platelet function, increasing the risk of bleeding, and is therefore contraindicated in patients with suspected or confirmed cerebrovascular bleeding, or those at high risk of hemorrhage.
Renal Toxicity: Risk of renal (kidney) injury, including acute renal failure, especially in patients with pre-existing kidney impairment, fluid depletion, or heart failure.
Hypersensitivity: Anaphylactic/anaphylactoid reactions, ranging from bronchospasm to shock, have been reported and can occur even without a prior history of exposure.

Safety Restrictions and Populations

The total combined duration of use for all forms of the medicine (oral, injectable) is officially not to exceed 5 days due to the increased risk of serious adverse events associated with higher doses and prolonged use. This drug is also contraindicated for use in the peri-operative setting of coronary artery bypass graft (CABG) surgery and during late pregnancy (after 30 weeks gestation) due to fetal risk. Elderly patients and those weighing less than 50 kg (110 lbs) are specifically identified as being at greater risk for serious adverse events, requiring dose adjustments in clinical practice.

Overdose and Emergency Response

Overdose Scope

Property	Content (Strictly Regulatory-Derived)
Documented overdose presentations	Nausea, vomiting, epigastric pain, drowsiness, and lethargy are common manifestations. Specific signs of toxicity may include hyperventilation and evidence of gastrointestinal bleeding, such as bloody or tarry stools.
Physiological systems affected	Gastrointestinal system (ulceration, bleeding, perforation), Renal system (acute renal failure, renal dysfunction), and Central Nervous System (respiratory depression, coma, hypertension).
Population-specific overdose notes	Elderly patients are documented as being at an increased risk for serious gastrointestinal events and are generally more sensitive to the drug’s potential adverse effects.
Emergency-response statements	Patients must be managed by symptomatic and supportive care. Official labeling states explicitly that no specific antidote is known for Ketorolac tromethamine overdose.
When immediate medical help is required	Seek immediate medical attention or emergency medical help right away upon the suspicion of overdose or if severe complications are suspected (e.g., life-threatening bleeding, signs of acute renal failure).

Official Overdose Statements

The severity classification includes rare but potentially life-threatening outcomes, such as acute renal failure, respiratory depression, and coma.
Supportive measures detailed in regulatory documents indicate that the use of activated charcoal may be considered in cases of large oral overdose within four hours of ingestion.
Regulatory documentation confirms that dialysis does not significantly clear the drug from the bloodstream, defining the procedural limits of hospital management.

Connection to the overall overdose profile:

The regulatory documentation defines the overdose profile by listing specific, documented physiological manifestations and emphasizing the potential for severe or fatal outcomes, particularly involving the GI and renal systems. This explicit risk documentation dictates the mandatory requirement to seek immediate medical attention for suspected overdose. The official guidance limits procedural interventions to symptomatic support, clarifying that the absence of a known antidote and the limited effectiveness of dialysis constrain the treatment approach.

Therapeutic Uses of Ketorolaco Genfar

What Ketorolaco Genfar Treats: Main Uses and Benefits

Ketorolaco Genfar is commonly used in situations involving certain distressing symptoms, where it may provide short-term supportive relief across several therapeutic domains. This medication is used to help with physical discomfort, often after a medical procedure.

It is applied across domains where additional symptomatic support is needed, assisting with the management of discomfort related to acute conditions, post-procedure recovery, and traumatic injury. The medication is used to help with symptom clusters that create noticeable physiological strain, offering supportive relief when symptoms interfere with daily functioning.

“This approach may support the patient during difficult episodes by contributing to easing the overall symptom load.”

Key Areas of Symptom Management

This medication plays a role in managing symptoms in conditions associated with acute episodes, post-operative discomfort, and functional strain caused by heightened physical symptoms. It may be part of symptomatic management in situations involving sudden onset or rapid escalation of physical discomfort.

Quick Fact: Relief for Acute Discomfort
Supports the process of easing the overall symptom burden during periods of heightened symptoms.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

Adults 17 years of age and older.
Patients requiring short-term management of moderately severe acute pain, not to exceed 5 days total duration for all routes of administration.

Populations for whom use is contraindicated:

Patients with active peptic ulcer disease, recent GI bleeding, GI perforation, or a history of these conditions.
Individuals with advanced renal impairment or those at risk for renal failure due to volume depletion.
Patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, or other high risk of bleeding.
Patients currently receiving aspirin or other NSAIDs due to the cumulative risk of serious adverse events.
Use during pregnancy (starting at 30 weeks gestation or later), during labor and delivery, and in breastfeeding women.
Use in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age-related eligibility rules:

Pediatric Patients (under 17 years): Safety and efficacy have not been established, and use is not indicated for this group.
Older Adults (65 years and older): Classified as a special population requiring extreme caution; use requires reduced dosages.

Eligibility-related restrictions:

Use is not indicated for minor or chronic painful conditions.
Patients with moderately elevated serum creatinine or those weighing under 50 kg must use a reduced dosage.

Connection to the overall eligibility profile: The regulatory profile strictly defines who can and cannot use the medicine, primarily through a clear set of absolute contraindications related to serious gastrointestinal, renal, and bleeding risks associated with this potent NSAID. For eligible adult populations, use is further restricted to a maximum duration of five days and mandatory dosage reductions apply to special populations, such as the elderly, to mitigate documented risks.

What should I know about interactions with other medicines?

Ketorolaco Genfar (ketorolac) is a nonsteroidal anti-inflammatory drug (NSAID) and should be used with caution, as it can interact with various other medications, potentially increasing the risk of serious side effects. Consult your healthcare provider or pharmacist about all drugs, supplements, and herbal products you are currently taking.

Medications with Increased Risk

Certain combinations are generally discouraged due to significant risks:

Drug Class	Examples	Potential Risk
Other NSAIDs	Ibuprofen, Naproxen, Aspirin	Increased risk of gastrointestinal (GI) bleeding and kidney problems. Concurrent use is contraindicated.
Anticoagulants	Warfarin, Heparin	Significantly increased risk of serious or fatal bleeding.
Antiplatelet Agents	Clopidogrel, Ticagrelor	Increased risk of bleeding.
Probenecid		Increased ketorolac concentration in the body, leading to higher toxicity risk. Contraindicated.

Interactions Affecting Efficacy and Toxicity

Ketorolac can also interact with other drugs by affecting their concentration or its own effect on the body:

Diuretics (e.g., Furosemide, Thiazides): Ketorolac may reduce the blood pressure-lowering and sodium-excreting effects of these medications, potentially leading to fluid retention and reduced diuretic efficacy.
ACE Inhibitors/ARBs (e.g., Lisinopril, Losartan): Combining with ketorolac may increase the risk of kidney function impairment, especially in older or dehydrated patients.
Lithium (for Bipolar Disorder): Ketorolac can increase plasma lithium levels, which may result in lithium toxicity.
Methotrexate (for Cancer, Arthritis): Ketorolac can increase the concentration and toxicity of methotrexate.
SSRI Antidepressants (e.g., Fluoxetine, Sertraline): Concurrent use may increase the risk of GI bleeding.

Alcohol consumption should be avoided while taking Ketorolaco Genfar, as it significantly raises the risk of gastrointestinal irritation and bleeding.

Mechanism of Action

Targeting the Cyclooxygenase Enzyme System

This drug functions as an inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which are integral to various signaling processes throughout the body. By binding to and blocking these enzymes, the drug engages a mechanism that interrupts the synthesis of key local signaling molecules, which results in the modulation of their availability.

Interrupting the Prostaglandin Pathway

The central action of inhibiting the COX enzymes directly interferes with the arachidonic acid cascade, significantly reducing the production of prostaglandins. The modulation of the biosynthetic pathway results in reduced sensitization of peripheral nerve endings and decreased regulation of vascular permeability.

Modulating Nerve Signal Propagation

The resulting reduction in prostaglandin levels modifies the activity of nerve endings, as these molecules are known to sensitize peripheral nerve endings and intensify signal propagation. The mechanism acts by limiting this chemical sensitization, resulting in a reduction in the rate and intensity of signal propagation within nerve pathways.

Dosage and Administration Information

How to Use Ketorolaco Genfar – Official Administration Guidelines

Ketorolaco Genfar (ketorolac tromethamine) is structurally defined for short-term, acute systemic use and is governed by strict regulatory instructions regarding administration route, dosage, and duration. Its use is limited to a sequential approach, typically initiated by injection and continued with tablets, with a non-negotiable time constraint.

Core Administration Rules

The medicine is officially available and used via Intravenous (IV), Intramuscular (IM), Oral (tablet), and Intranasal (nasal spray) routes for systemic application. The oral form is explicitly not to be used as an initial treatment; it is intended only as continuation therapy following parenteral (IV or IM) administration.

Administration Constraint	Labeled Instruction
Max Combined Duration	Total use by any systemic route must not exceed five days in adults.
Standard IV/IM Frequency	Typically administered every 6 hours in the multiple-dose regimen.
IV Administration Detail	The IV bolus must be administered slowly, over no less than 15 seconds.

Dosing and Population-Specific Adjustments

Official labeling defines strict dose ceilings based on a patient’s profile. For non-elderly adults weighing at least 50 kg, the maximum parenteral dose is 120 mg per day. The oral continuation dose is capped at 40 mg per day.

Crucially, a reduced maximum daily dose of 60 mg (IV/IM) is mandatory for patients 65 years of age or older, those weighing less than 50 kg, and those with renal impairment. The adherence to these dosing and duration limitations is central to the officially documented use of the medicine.

Recent Clinical Evidence

The research base for Ketorolaco Genfar (Ketorolac tromethamine) has been established in controlled clinical trials and systematic reviews. Research was conducted to explore specific outcomes related to physical discomfort and systemic or functional imbalance where the medicine was studied. Research describes group patterns and not personal outcomes, reflecting the specific conditions under which the studies were conducted.

Evidence for Use in Acute Systemic Analgesia

Research was relevant in trials assessing short-term or episodic symptom patterns for conditions involving periods of heightened symptoms, such as pain experienced in emergency settings. This evidence is derived mostly from Randomized Controlled Trials (RCTs) in adult populations. Studies explored data show patterns related to concurrent opioid use. Long-term effects are not fully established; limited information for long-term outcomes is available. The follow-up durations were limited, typically focused on the hours or first few days of treatment.

Evidence for Use in Postoperative Pain Management

A substantial body of research was evaluated in research exploring outcomes related to physical discomfort following a range of surgical procedures. Studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning in patients who had undergone procedures like orthopedic or dental surgery. Findings indicate that data show patterns related to opioid requirements when Ketorolac was included in the patient's pain management plan. The evidence for this indication data show patterns related to very short follow-up durations, with measurements frequently limited to the first 24 to 72 hours post-surgery.

Evidence for Use in Ophthalmic Conditions

Ketorolac was studied for its use as a topical eye solution in conditions associated with acute or disruptive episodes in the eye. Trials monitored local patient-reported outcomes describing perceived discomfort (e.g., ocular pain scores) and objective measurements of inflammation following specific eye procedures. Evidence is generally limited to short-term symptomatic management.

What is Still Uncertain in the Research Landscape

The primary uncertainty lies in the limited information for long-term outcomes and the durability of any observed effects. The subgroup findings are uncertain or heterogeneous regarding use in patients with pre-existing risk factors. Furthermore, comparative evidence is lacking for many direct comparisons against other nonsteroidal anti-inflammatory drugs (NSAIDs).

Frequently Asked Questions (FAQ)

Common questions about Ketorolaco Genfar (FAQ)

Q: What kind of pain is Ketorolaco Genfar most commonly prescribed for?

A: Official documents state that this medicine is indicated for the short-term management of moderately severe acute pain. The pain treated is described in official documents as requiring analgesia at the opioid level.

Q: What is the primary purpose of Ketorolaco Genfar after surgery?

A: The medicine is generally used in a postoperative setting to help manage moderately severe acute pain. The injectable form is indicated for initial use in these scenarios, followed by the tablet form.

Q: How long does the effect of Ketorolaco Genfar usually last?

A: The duration of the analgesic effect is described in official documents as being approximately 4 to 6 hours. This figure applies to the injectable form.

Q: Can taking Ketorolaco Genfar affect my liver function?

A: Official documents state that the drug is used with caution in patients with impaired liver function or pre-existing liver conditions. Though rare, severe hepatic (liver) reactions, including liver failure, have been reported with NSAID use.

Q: Is it necessary to take Ketorolaco Genfar with food?

A: Patient information suggests taking the tablets with food or an antacid as a way to potentially lessen stomach upset.

Q: Can a person who is breastfeeding generally use Ketorolaco Genfar?

A: Use of this medicine is contraindicated (advised against) for women who are breastfeeding. This is because the drug's active ingredient has been found to pass into breast milk.

Q: Does the injectable form of Ketorolaco Genfar work faster than the tablet?

A: The injectable form is intended for initial, rapid management, with pain relief often starting within about 30 minutes. The oral tablet form is prescribed only for continuation therapy following the injectable route.

Q: How quickly does Ketorolaco Genfar typically start working?

A: The analgesic effect is reported to begin approximately 30 minutes after administration of the injectable form.

Q: Can Ketorolaco Genfar cause stomach problems or upset?

A: Commonly reported adverse effects include minor stomach issues such as nausea, heartburn, indigestion, and mild abdominal pain.

Q: Can a person take Ketorolaco Genfar if they have high blood pressure?

A: NSAIDs like this one may cause a new onset of high blood pressure or the worsening of pre-existing hypertension. Regulatory warnings indicate that patients with high blood pressure require close monitoring, especially when treatment begins.

Q: What happens if Ketorolaco Genfar is taken with alcohol?

A: Official warnings state that taking this drug with alcohol significantly increases the risk of serious adverse events, specifically gastrointestinal irritation and bleeding. For this reason, official warnings describe alcohol consumption during use as being generally avoided.

Q: Can Ketorolaco Genfar cause drowsiness or affect driving?

A: Reported adverse effects include dizziness, drowsiness, and somnolence (sleepiness). Although the drug is not an opioid, these potential effects are listed in official documents.

Q: Is it possible for Ketorolaco Genfar to cause fluid retention or swelling?

A: Yes, regulatory documents list edema (swelling) as a reported adverse event. This may appear as swelling of the face, hands, lower legs, ankles, or feet.

Q: Does Ketorolaco Genfar have the potential for dependence or addiction?

A: The medicine is classified as a non-opioid analgesic. Official documents state that it does not possess sedative or anxiety-reducing properties, and it is not associated with the dependence or addiction potential seen in opioid medications.

Q: Can Ketorolaco Genfar cause issues with bleeding or bruising?

A: The medicine can affect platelet function, which may lead to an increase in bleeding time. Reported effects include bruising and purpura, which is a rash of small areas of bleeding under the skin.

Q: Can taking Ketorolaco Genfar affect the results of any lab tests?

A: Yes, regulatory documents list potential effects on lab values. Specific effects described include elevations of liver enzymes and an increase in bleeding time.

Q: What are the signs of a serious, though rare, side effect from Ketorolaco Genfar?

A: Signs of severe effects include sudden chest pain, shortness of breath, weakness on one side of the body, slurred speech, bloody vomit, or stools that are black and tarry. The onset of these severe effects is described in official documents as requiring urgent medical evaluation.

Q: Is Ketorolaco Genfar safe to take at the same time as paracetamol (acetaminophen)?

A: Paracetamol (acetaminophen) is not specifically listed in the regulatory documents as a drug that is strictly contraindicated for concurrent use with this medicine.

Q: Does Ketorolaco Genfar have known interactions with common antidepressant medications?

A: Yes, regulatory information describes known interactions with Selective Serotonin Reuptake Inhibitors (SSRIs), which are a class of antidepressants. Concurrent use with SSRIs may increase the risk of gastrointestinal bleeding.

Q: Can Ketorolaco Genfar cause confusion or mood changes in some people?

A: Reported effects on the nervous system include confusion, abnormal thinking, anxiety, depression, and euphoria.

Q: Is it possible to experience headache as a side effect of Ketorolaco Genfar?

A: Yes, headache is listed in the regulatory documents as a commonly reported adverse event.

Q: Can people with asthma generally use Ketorolaco Genfar?

A: The medicine is contraindicated in patients who have experienced asthma or allergic-type reactions after taking aspirin or other NSAIDs. Caution is generally advised for patients with pre-existing asthma.

Q: What should a person know about taking Ketorolaco Genfar if they have heart issues?

A: The drug carries a Boxed Warning for an increased risk of serious cardiovascular events such as heart attack and stroke. It is also strictly contraindicated for use around the time of coronary artery bypass graft (CABG) surgery.

Q: Are there specific patient groups where Ketorolaco Genfar is used with special caution?

A: Yes, regulatory documents identify groups requiring special caution or dose adjustment. These groups include patients aged 65 years or older, those weighing less than 50 kg, and those with renal (kidney) or hepatic (liver) impairment.

Q: Is Ketorolaco Genfar safe for use in older adults (seniors)?

A: Older adults (65 years and older) are identified as a population at increased risk for serious adverse events. Official documents require a reduction in the maximum daily dose for this group.

Q: What is the typical age range for patients who receive Ketorolaco Genfar?

A: Official documents state that the medicine is authorized for use in adults aged 17 years and older. It is not indicated for use in pediatric patients younger than 17.

Q: What are the descriptive terms used by official sources to explain the drug's purpose?

A: Official sources describe the drug as a potent NSAID analgesic. Its purpose is defined as the short-term management of moderately severe acute pain that is described as requiring analgesia at the opioid level.

How should Ketorolaco Genfar be stored and disposed of?

Storage and Disposal of Ketorolaco Genfar

Official regulatory guidelines strictly define the conditions necessary for storing and disposing of Ketorolac Tromethamine products.

Required Storage Conditions

Ketorolac tablets and the injectable solution must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The injectable solution must not be frozen and must be protected from light by remaining in its original carton until the time of use. It requires a visual inspection for particulate matter or discoloration before use. The medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Ketorolac should be disposed of according to local regulations. Regulatory documents generally specify that the product should not be thrown into household waste or wastewater to minimize environmental impact.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.